pharma · Pulmonary Arterial Hypertension (PAH)
AOP Orphan Pharmaceuticals
AOP Orphan Pharmaceuticals GmbH
AOP Orphan Pharmaceuticals is a pharma organization headquartered in Wien, AT. Primary therapeutic focus areas include Pulmonary Arterial Hypertension (PAH). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s),
Company details
- Status
- Public
- HQ
- Wien, AT
- Programs
- 2
- Drugs
- 1
- Patents
- 7
LB-208, LB-208
Phase 2 · small molecule · Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
LB-208, LB-208 for Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS) is a Phase 2 program (small_molecule) at AOP Orphan Pharmaceuticals GmbH with 1 ClinicalTrials.gov record(s).
Internal code LB208-1-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AOP Orphan Pharmaceuticals GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
- Status
- active
- Trials
- 1